Claire Pomeroy - Becton Dickinson Independent Director
| BDX Stock | USD 230.23 1.62 0.70% |
Director
Ms. Claire Pomeroy is Independent Director of the Company. Since 2013, she has served as the President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. Prior thereto, Dr. Pomeroy served as Dean of the University of California, Davis School of Medicine, and Chief Executive Officer of the UC Davis Health System. Dr. Pomeroy also is Chair of the Board of Directors of the Foundation for Biomedical Research and the Sierra Health Foundation, and Vice Chairman of the Board of Trustees of The New York Academy of Medicine. She is a member of the Board of Trustees of the New York Blood Center and the Morehouse School of Medicine since 2014.
| Age | 65 |
| Tenure | 11 years |
| Address | 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880 |
| Phone | 201 847 6800 |
| Web | https://www.bd.com |
Becton Dickinson Management Efficiency
The company has Return on Asset of 0.037 % which means that on every $100 spent on assets, it made $0.037 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0684 %, implying that it generated $0.0684 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2025, whereas Return On Capital Employed is likely to drop 0.05 in 2025. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 56.5 B in 2025, whereas Net Tangible Assets are likely to drop (9.1 B) in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Hofmann | West Pharmaceutical Services | 68 | |
| Mark Buthman | West Pharmaceutical Services | 60 | |
| Richard Sulpizio | ResMed Inc | 70 | |
| Carol Burt | ResMed Inc | 62 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| Karen Drexler | ResMed Inc | 60 | |
| Deborah Tanner | West Pharmaceutical Services | 57 | |
| Ronald Taylor | ResMed Inc | 72 | |
| Mark Kroll | Haemonetics | 67 | |
| William Feehery | West Pharmaceutical Services | 50 | |
| George Babich | Teleflex Incorporated | 69 | |
| Harjit Gill | ResMed Inc | 55 | |
| Gary Petersmeyer | The Cooper Companies, | 73 | |
| Maria Rivas | The Cooper Companies, | 57 | |
| Robert Abernathy | Haemonetics | 66 | |
| Robert Friel | West Pharmaceutical Services | 65 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| Paula Johnson | West Pharmaceutical Services | 59 | |
| Stephen Klasko | Teleflex Incorporated | 67 | |
| Candace Duncan | Teleflex Incorporated | 67 | |
| John Heinmiller | Teleflex Incorporated | 66 | |
Management Performance
| Return On Equity | 0.0684 | ||||
| Return On Asset | 0.037 |
Becton Dickinson Leadership Team
Elected by the shareholders, the Becton Dickinson's board of directors comprises two types of representatives: Becton Dickinson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Becton. The board's role is to monitor Becton Dickinson's management team and ensure that shareholders' interests are well served. Becton Dickinson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Becton Dickinson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Reidy, Chief Financial Officer, Executive Vice President, Chief Administrative Officer | ||
| Denise Fleming, Executive Officer | ||
| Rebecca Rimel, Independent Director | ||
| Thomas Spoerel, Senior Vice President, Controller and Chief Accounting Officer, Principal Accounting Officer | ||
| Claire Fraser, Independent Director | ||
| Alexandre Conroy, Executive Vice President, Chief Integrated Supply Chain Officer | ||
| Ami Simunovich, Regulatory Quality | ||
| Christopher CPA, Executive CFO | ||
| Jeffrey Henderson, Independent Director | ||
| John DeFord, Executive Vice President, Chief Technology Officer | ||
| Greg Rodetis, Head Relations | ||
| Christopher Jones, Independent Director | ||
| Antoinette Segreto, Senior Taxes | ||
| Claire Pomeroy, Independent Director | ||
| Patrick Kaltenbach, Executive Vice President, President - Life Sciences | ||
| Michael Garrison, Executive segment | ||
| Catherine Burzik, Independent Director | ||
| Claudia Curtis, Chief VP | ||
| Charles Bodner, Senior Vice President Corporate Finance, and Chief Accounting Officer and Principal Accounting Officer | ||
| R Eckert, Independent Director | ||
| Roland Goette, Executive Vice President and Presidentident - EMEA | ||
| James Lim, Executive Vice President and President, Greater Asia | ||
| Antoine Ezell, Executive Vice President and Presidentident, North America and Chief Marketing Officer | ||
| Thomas Polen, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer | ||
| Marshall Larsen, Lead Independent Director | ||
| Troy Kirkpatrick, VP PR | ||
| Alberto Mas, Executive Vice President and President - Life Sciences Segment | ||
| Michelle Quinn, Executive Counsel | ||
| Carla Burigatto, Senior Officer | ||
| Pamela Spikner, Chief VP | ||
| Shana Neal, Executive Officer | ||
| Ching leong, Executive Vice President and President Greater Asia | ||
| Elizabeth McCombs, Executive Officer | ||
| Bertram Scott, Independent Director | ||
| FACC MD, Chief VP | ||
| Samrat Esq, Public Devel | ||
| Richard Byrd, Executive Segment | ||
| Francesca DeMartino, VP Relations | ||
| David Hickey, Executive Vice President and President, Life Sciences Segment | ||
| Betty Larson, Executive Vice President- Human Resources, Chief Human Resources | ||
| James Borzi, Executive Vice President - Global Operations, Chief Supply Chain Officer | ||
| William Brown, Independent Director | ||
| Simon Campion, Executive Vice President and President BD Interventional Segment | ||
| Carrie Byington, Independent Director | ||
| Vincent Forlenza, Chairman, CEO and President and Chairman of Executive Committee | ||
| Christopher DelOrefice, Chief Financial Officer, Executive Vice President | ||
| Samrat Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel | ||
| David Melcher, Independent Director | ||
| Timothy Ring, Independent Director |
Becton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Becton Dickinson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0684 | ||||
| Return On Asset | 0.037 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 84.6 B | ||||
| Shares Outstanding | 287.14 M | ||||
| Shares Owned By Insiders | 0.55 % | ||||
| Shares Owned By Institutions | 93.72 % | ||||
| Number Of Shares Shorted | 2.94 M | ||||
| Price To Earning | 45.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Becton Stock Analysis
When running Becton Dickinson's price analysis, check to measure Becton Dickinson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Becton Dickinson is operating at the current time. Most of Becton Dickinson's value examination focuses on studying past and present price action to predict the probability of Becton Dickinson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Becton Dickinson's price. Additionally, you may evaluate how the addition of Becton Dickinson to your portfolios can decrease your overall portfolio volatility.